This study is testing a new drug called CJRB-101 alongside an existing cancer treatment, pembrolizumab (a checkpoint inhibitor, which helps your immune system fight cancer), for people with advanced or metastatic (spread to other parts of the body) non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), or melanoma. Researchers want to see if this combination is safe, how well people tolerate it, and if it helps shrink tumors. You would receive CJRB-101 capsules daily and pembrolizumab injections every three weeks. The study is open to adults aged 18 and older who have measurable tumors. It's currently unclear if the study is actively enrolling participants.

Study design

This is an open-label study, meaning you and your doctors will know which treatments you are receiving. It plans to enroll 160 participants across centers in the USA and Republic of Korea.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety and how well the treatment works will be measured for a maximum of 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.